Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,077 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial.
Koch EAT, Petzold A, Wessely A, Dippel E, Eckstein M, Gesierich A, Gutzmer R, Hassel JC, Knorr H, Kreuzberg N, Leiter U, Loquai C, Meier F, Meissner M, Mohr P, Pföhler C, Rahimi F, Schadendorf D, Schlaak M, Thoms KM, Ugurel S, Utikal J, Weichenthal M, Schuler-Thurner B, Berking C, Heppt MV. Koch EAT, et al. Among authors: schadendorf d. Front Med. 2023 Oct;17(5):878-888. doi: 10.1007/s11684-023-0993-y. Epub 2023 Jul 4. Front Med. 2023. PMID: 37432641 Clinical Trial.
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, Schadendorf D, Ugurel S. Paschen A, et al. Among authors: schadendorf d. Clin Cancer Res. 2009 Aug 15;15(16):5208-15. doi: 10.1158/1078-0432.CCR-09-0886. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671853
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C. Hauschild A, et al. Among authors: schadendorf d. J Clin Oncol. 2010 Feb 10;28(5):841-6. doi: 10.1200/JCO.2009.23.1704. Epub 2010 Jan 4. J Clin Oncol. 2010. PMID: 20048184 Clinical Trial.
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.
Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, Bostroem A, Heese O, Koelbl O, Garbe C, Schadendorf D; Dermatologic Cooperative Oncology Group and the National Interdisciplinary Working Group on Melanoma. Eigentler TK, et al. Among authors: schadendorf d. Cancer. 2011 Apr 15;117(8):1697-703. doi: 10.1002/cncr.25631. Epub 2010 Nov 8. Cancer. 2011. PMID: 21472716 Free article.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Chapman PB, et al. Among authors: schadendorf d. N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639808 Free PMC article. Clinical Trial.
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial.
Hofmann MA, Hauschild A, Mohr P, Garbe C, Weichenthal M, Trefzer U, Drecoll U, Tilgen W, Schadendorf D, Kaatz M, Ulrich J. Hofmann MA, et al. Among authors: schadendorf d. Melanoma Res. 2011 Dec;21(6):516-23. doi: 10.1097/CMR.0b013e3283485ff0. Melanoma Res. 2011. PMID: 22076216 Clinical Trial.
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Flaherty KT, et al. Among authors: schadendorf d. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4. N Engl J Med. 2012. PMID: 22663011 Free article. Clinical Trial.
New developments in biomarkers for melanoma.
Griewank KG, Ugurel S, Schadendorf D, Paschen A. Griewank KG, et al. Among authors: schadendorf d. Curr Opin Oncol. 2013 Mar;25(2):145-51. doi: 10.1097/CCO.0b013e32835dafdf. Curr Opin Oncol. 2013. PMID: 23334230 Review.
1,077 results